$ANIP
ANI PHARMACEUTICALS INC

2022 Q2 Form 10-Q Financial Statement

#000102302422000017 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2021 Q4 2021 Q2
Revenue $73.86M $60.93M $48.63M
YoY Change 51.89% 6.42% 0.32%
Cost Of Revenue $35.29M $33.90M $22.31M
YoY Change 58.17% 38.13% 7.82%
Gross Profit $38.56M $27.03M $26.31M
YoY Change 46.56% -17.36% -5.27%
Gross Profit Margin 52.21% 44.36% 54.11%
Selling, General & Admin $31.96M $30.71M $18.82M
YoY Change 69.81% 113.68% -11.28%
% of Gross Profit 82.88% 113.6% 71.53%
Research & Development $4.165M $3.140M $2.805M
YoY Change 48.48% -14.67% -7.58%
% of Gross Profit 10.8% 11.62% 10.66%
Depreciation & Amortization $14.17M $13.68M $11.32M
YoY Change 25.17% 25.54% 1.13%
% of Gross Profit 36.76% 50.62% 43.04%
Operating Expenses $36.12M $48.03M $21.63M
YoY Change 67.04% 65.91% -10.82%
Operating Profit -$12.91M -$21.00M -$15.55M
YoY Change -16.97% -6444.11% 37.55%
Interest Expense -$6.669M -$4.440M -$2.531M
YoY Change 163.49% 74.12% 7.43%
% of Operating Profit
Other Income/Expense, Net $764.0K -$2.690M -$67.00K
YoY Change -1240.3% 1581.25% -42.24%
Pretax Income -$18.82M -$30.85M -$18.15M
YoY Change 3.67% 1196.34% 31.53%
Income Tax -$3.900M -$6.717M -$4.000M
% Of Pretax Income
Net Earnings -$14.92M -$24.14M -$14.11M
YoY Change 5.79% 563.99% 14.35%
Net Earnings / Revenue -20.21% -39.61% -29.01%
Basic Earnings Per Share -$0.94 -$1.17
Diluted Earnings Per Share -$0.94 -$1.701M -$1.17
COMMON SHARES
Basic Shares Outstanding 16.27M 12.09M
Diluted Shares Outstanding 16.27M 12.09M

Balance Sheet

Concept 2022 Q2 2021 Q4 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.39M $100.3M $24.26M
YoY Change 161.26% 1169.62% -12.42%
Cash & Equivalents $63.39M $100.3M $24.26M
Short-Term Investments
Other Short-Term Assets $14.05M $7.589M $4.881M
YoY Change 187.77% 28.63% 57.45%
Inventory $92.55M $81.69M $67.63M
Prepaid Expenses $6.026M $7.589M $4.881M
Receivables $150.4M $128.5M $92.65M
Other Receivables $2.013M $3.667M $2.375M
Total Short-Term Assets $322.4M $321.8M $191.8M
YoY Change 68.09% 88.92% 22.52%
LONG-TERM ASSETS
Property, Plant & Equipment $43.77M $52.67M $40.33M
YoY Change 8.52% 27.63% 0.99%
Goodwill $28.22M $27.89M $3.580M
YoY Change 688.3% 674.67% 0.0%
Intangibles $269.6M $294.1M $180.2M
YoY Change 49.61% 56.02% -12.42%
Long-Term Investments
YoY Change
Other Assets $5.762M $2.205M $720.0K
YoY Change 700.28% 174.94% -34.25%
Total Long-Term Assets $428.9M $449.8M $288.4M
YoY Change 48.75% 54.65% -6.63%
TOTAL ASSETS
Total Short-Term Assets $322.4M $321.8M $191.8M
Total Long-Term Assets $428.9M $449.8M $288.4M
Total Assets $751.3M $771.6M $480.2M
YoY Change 56.48% 67.31% 3.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.64M $22.97M $12.98M
YoY Change 113.0% 103.95% -8.67%
Accrued Expenses $11.51M $7.650M $11.58M
YoY Change -0.66% 211.48% 277.76%
Deferred Revenue $100.0K $100.0K
YoY Change 0.0% 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $850.0K $850.0K $15.18M
YoY Change -94.4% -93.58% 23.14%
Total Short-Term Liabilities $96.31M $87.54M $89.45M
YoY Change 7.67% 11.42% 13.11%
LONG-TERM LIABILITIES
Long-Term Debt $286.1M $286.5M $189.5M
YoY Change 50.95% 66.15% 6.55%
Other Long-Term Liabilities $1.011M $7.801M $9.263M
YoY Change -89.09% -46.13% -45.77%
Total Long-Term Liabilities $287.1M $294.3M $198.8M
YoY Change 44.43% 57.45% 1.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $96.31M $87.54M $89.45M
Total Long-Term Liabilities $287.1M $294.3M $198.8M
Total Liabilities $414.4M $412.9M $288.2M
YoY Change 43.76% 55.51% 5.18%
SHAREHOLDERS EQUITY
Retained Earnings -$83.63M -$47.77M -$18.99M
YoY Change 340.34% 860.68% 972.39%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $312.1M $333.9M $191.9M
YoY Change
Total Liabilities & Shareholders Equity $751.3M $771.6M $480.2M
YoY Change 56.48% 67.31% 3.17%

Cashflow Statement

Concept 2022 Q2 2021 Q4 2021 Q2
OPERATING ACTIVITIES
Net Income -$14.92M -$24.14M -$14.11M
YoY Change 5.79% 563.99% 14.35%
Depreciation, Depletion And Amortization $14.17M $13.68M $11.32M
YoY Change 25.17% 25.54% 1.13%
Cash From Operating Activities -$11.48M -$12.18M $239.0K
YoY Change -4905.02% 113.4% -98.86%
INVESTING ACTIVITIES
Capital Expenditures -$1.321M -$356.0K -$930.0K
YoY Change 42.04% -83.13% 29.17%
Acquisitions
YoY Change
Other Investing Activities $717.0K -$81.86M -$21.02M
YoY Change -103.41% 818470.0% 891.37%
Cash From Investing Activities -$604.0K -$82.21M -$21.95M
YoY Change -97.25% 3777.97% 672.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.437M 179.4M 20.90M
YoY Change -106.87% -8219.64% -294.63%
NET CHANGE
Cash From Operating Activities -11.48M -12.18M 239.0K
Cash From Investing Activities -604.0K -82.21M -21.95M
Cash From Financing Activities -1.437M 179.4M 20.90M
Net Change In Cash -13.52M 85.05M -805.0K
YoY Change 1580.12% -947.07% -111.03%
FREE CASH FLOW
Cash From Operating Activities -$11.48M -$12.18M $239.0K
Capital Expenditures -$1.321M -$356.0K -$930.0K
Free Cash Flow -$10.16M -$11.83M $1.169M
YoY Change -969.38% 228.58% -94.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Central Index Key
EntityCentralIndexKey
0001023024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 anip Class C Special Stock Value
ClassCSpecialStockValue
CY2021Q4 anip Class C Special Stock Value
ClassCSpecialStockValue
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31812
dei Entity Registrant Name
EntityRegistrantName
ANI PHARMACEUTICALS, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
58-2301143
dei Entity Address Address Line1
EntityAddressAddressLine1
210 Main Street West
dei Entity Address City Or Town
EntityAddressCityOrTown
Baudette
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
56623
dei City Area Code
CityAreaCode
218
dei Local Phone Number
LocalPhoneNumber
634-3500
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ANIP
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63385000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100300000
CY2022Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
150428000
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
105260000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
150410000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
128526000
CY2022Q2 us-gaap Inventory Net
InventoryNet
92545000
CY2021Q4 us-gaap Inventory Net
InventoryNet
81693000
CY2022Q2 anip Prepaid Income Taxes Net
PrepaidIncomeTaxesNet
2013000
CY2021Q4 anip Prepaid Income Taxes Net
PrepaidIncomeTaxesNet
3667000
CY2022Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
8020000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6026000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7589000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
322399000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
321775000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
71042000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
75627000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27271000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22956000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43771000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52671000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5001000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5001000
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
76587000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
67936000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
269593000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
294122000
CY2022Q2 us-gaap Goodwill
Goodwill
28221000
CY2021Q4 us-gaap Goodwill
Goodwill
27888000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5762000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2205000
CY2022Q2 us-gaap Assets
Assets
751334000
CY2021Q4 us-gaap Assets
Assets
771598000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
850000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
850000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
27641000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22967000
CY2022Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6295000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6225000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5682000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8522000
CY2022Q2 anip Accrued Government Rebates
AccruedGovernmentRebates
9440000
CY2021Q4 anip Accrued Government Rebates
AccruedGovernmentRebates
5492000
CY2022Q2 anip Returned Goods Reserve
ReturnedGoodsReserve
34899000
CY2021Q4 anip Returned Goods Reserve
ReturnedGoodsReserve
35831000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11505000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7650000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1181000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
96312000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
87537000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
286095000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
286520000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
30958000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
31000000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1011000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7801000
CY2022Q2 us-gaap Liabilities
Liabilities
414376000
CY2021Q4 us-gaap Liabilities
Liabilities
412858000
CY2022Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
24850000
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
24850000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
139112
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
82662
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
4736000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3135000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
395043000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
387844000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83630000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47765000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5430000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3055000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
312108000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
333890000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
751334000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
771598000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73855000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48625000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138332000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103146000
CY2022Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
35294000
CY2021Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
22314000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
69565000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
42299000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4165000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2805000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9439000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5773000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31958000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18820000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-342000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60775000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36407000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
13764000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
11324000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
28321000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
22222000
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1095000
anip Cortrophin Pre Launch Charges
CortrophinPreLaunchCharges
553000
CY2022Q2 us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
2570000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2021Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-8400000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-8400000
CY2021Q2 anip Cortrophin Pre Launch Charges
CortrophinPreLaunchCharges
515000
anip Cortrophin Pre Launch Charges
CortrophinPreLaunchCharges
0
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
2570000
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
0
CY2022Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
112000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
112000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
86768000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
64178000
us-gaap Costs And Expenses
CostsAndExpenses
170440000
us-gaap Costs And Expenses
CostsAndExpenses
115654000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12913000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15553000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32108000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12508000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6669000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2531000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-13282000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4985000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
764000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-67000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
675000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-582000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18818000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18151000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44715000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18075000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3895000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4045000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9662000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4055000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14923000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14106000
us-gaap Net Income Loss
NetIncomeLoss
-35053000
us-gaap Net Income Loss
NetIncomeLoss
-14020000
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
407000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
812000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15330000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14106000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35865000
us-gaap Net Income Loss
NetIncomeLoss
-14020000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
750000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16272000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12085000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16205000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12045000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16272000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12085000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16205000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12045000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14923000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14106000
us-gaap Net Income Loss
NetIncomeLoss
-35053000
us-gaap Net Income Loss
NetIncomeLoss
-14020000
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
2718000
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-401000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
8485000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
6004000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2718000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-401000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8485000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6004000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12205000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14507000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26568000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8016000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
203712000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2844000
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
468000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
337000
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-401000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14106000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
191917000
CY2022Q1 anip Stockholders Equity Attributable To Parent And Temporary Equity
StockholdersEquityAttributableToParentAndTemporaryEquity
346094000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3756000
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
483000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
203000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
407000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2718000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14923000
CY2022Q2 anip Stockholders Equity Attributable To Parent And Temporary Equity
StockholdersEquityAttributableToParentAndTemporaryEquity
336958000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
195700000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4713000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
816000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
337000
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6004000
us-gaap Net Income Loss
NetIncomeLoss
-14020000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
191917000
CY2021Q4 anip Stockholders Equity Attributable To Parent And Temporary Equity
StockholdersEquityAttributableToParentAndTemporaryEquity
358740000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6993000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1601000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
206000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
812000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8485000
us-gaap Net Income Loss
NetIncomeLoss
-35053000
CY2022Q2 anip Stockholders Equity Attributable To Parent And Temporary Equity
StockholdersEquityAttributableToParentAndTemporaryEquity
336958000
us-gaap Net Income Loss
NetIncomeLoss
-35053000
us-gaap Net Income Loss
NetIncomeLoss
-14020000
us-gaap Share Based Compensation
ShareBasedCompensation
6993000
us-gaap Share Based Compensation
ShareBasedCompensation
4713000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-11378000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-6676000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
28731000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
22222000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1969000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1141000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-342000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
575000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21884000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3145000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10852000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2823000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1563000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1202000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4047000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1688000
anip Increase Decrease In Royalty Payable
IncreaseDecreaseInRoyaltyPayable
70000
anip Increase Decrease In Royalty Payable
IncreaseDecreaseInRoyaltyPayable
-1719000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
1654000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-6281000
anip Increase Decrease Accrued Government Rebates
IncreaseDecreaseAccruedGovernmentRebates
3948000
anip Increase Decrease Accrued Government Rebates
IncreaseDecreaseAccruedGovernmentRebates
914000
anip Increase Decrease In Returned Goods Reserve
IncreaseDecreaseInReturnedGoodsReserve
-903000
anip Increase Decrease In Returned Goods Reserve
IncreaseDecreaseInReturnedGoodsReserve
4754000
anip Increase Decrease Of Accrued Expenses Compensation And Others
IncreaseDecreaseOfAccruedExpensesCompensationAndOthers
1186000
anip Increase Decrease Of Accrued Expenses Compensation And Others
IncreaseDecreaseOfAccruedExpensesCompensationAndOthers
7003000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30426000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20909000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
33000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
229000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
21057000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3270000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1630000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
750000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2782000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22687000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1500000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
5206000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
24000000
us-gaap Payments Of Dividends
PaymentsOfDividends
812000
us-gaap Payments Of Dividends
PaymentsOfDividends
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
206000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
336000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
141000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1601000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
816000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3707000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18173000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-36915000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
16395000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105301000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12867000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68386000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29262000
CY2022Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
6122000
CY2021Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2386000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
12180000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4690000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100300000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7864000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5001000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5003000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105301000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12867000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63385000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24261000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5001000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5001000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68386000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29262000
us-gaap Interest Paid Net
InterestPaidNet
11400000
us-gaap Interest Paid Net
InterestPaidNet
3953000
us-gaap Income Taxes Paid
IncomeTaxesPaid
124000
us-gaap Income Taxes Paid
IncomeTaxesPaid
8360000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
81000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
779000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
119000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our manufacturing capabilities. Our four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey, and one is located in Oakville, Ontario, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. On June 2, 2022, we announced that we intend to cease operations at our Oakville, Ontario, Canada manufacturing plant by first quarter 2023. This action is part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (“Novitium”) in November 2021. We will transition the majority of products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites, and we are seeking to find potential buyers for the Oakville site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="font-weight:normal;">Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe the going-concern basis is appropriate for the accompanying unaudited interim condensed consolidated financial statements based on our current operating plan and business strategy for the 12 months following the issuance of this report.</span></p>
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
590000
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
176000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.</p>
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73855000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48625000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138332000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103146000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73855000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48625000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138332000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103146000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
3700000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
10300000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
100000
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
100000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.21
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
352000
CY2022Q2 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
19000
CY2021Q2 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
31000
us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
49000
us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
57000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
6693000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2531000
us-gaap Interest Expense Debt
InterestExpenseDebt
13312000
us-gaap Interest Expense Debt
InterestExpenseDebt
4985000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14923000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14106000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14923000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14106000
us-gaap Net Income Loss
NetIncomeLoss
-35053000
us-gaap Net Income Loss
NetIncomeLoss
-14020000
us-gaap Net Income Loss
NetIncomeLoss
-35053000
us-gaap Net Income Loss
NetIncomeLoss
-14020000
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
407000
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
407000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
812000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
812000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15330000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14106000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15330000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14106000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35865000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14020000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35865000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14020000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16272000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12085000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16272000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12085000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16205000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12045000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16205000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12045000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16272000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12085000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16205000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12045000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.21
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2700000
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
59176000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
51350000
CY2022Q2 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
6414000
CY2021Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
5475000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
879000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
652000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
33936000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
31969000
CY2022Q2 us-gaap Inventory Gross
InventoryGross
100405000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
89446000
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7860000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7753000
CY2022Q2 us-gaap Inventory Net
InventoryNet
92545000
CY2021Q4 us-gaap Inventory Net
InventoryNet
81693000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
500330000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
230737000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
500489000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
206367000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11900000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19700000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
100000
CY2022Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
100000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
24693000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
50770000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
49974000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
47870000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
34551000
CY2022Q2 anip Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
61735000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
269593000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1700000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
400000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3900000
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.207
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18800000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000000.0
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.223
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9700000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.216
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4100000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.224
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18100000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
143000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
43000
us-gaap Operating Lease Cost
OperatingLeaseCost
269000
us-gaap Operating Lease Cost
OperatingLeaseCost
92000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
54000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
13000
us-gaap Variable Lease Cost
VariableLeaseCost
120000
us-gaap Variable Lease Cost
VariableLeaseCost
21000
CY2022Q2 us-gaap Lease Cost
LeaseCost
197000
CY2021Q2 us-gaap Lease Cost
LeaseCost
56000
us-gaap Lease Cost
LeaseCost
389000
us-gaap Lease Cost
LeaseCost
113000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
251000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
482000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
468000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
248000
CY2022Q2 anip Lessee Operating Lease Liability To Be Paid Year Four And After
LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter
126000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1575000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
163000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1412000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
413000
CY2022Q2 anip Operating Lease Liability Other Noncurrent
OperatingLeaseLiabilityOtherNoncurrent
999000
CY2022Q2 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
3600000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
32053000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
31000000
anip Fair Value Measurement With Unobservable Inputs Reconciliation Measurement Period Adjustment
FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment
300000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1095000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-342000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
30958000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
30958000
CY2022Q2 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
3636000
CY2021Q4 us-gaap Interest Rate Derivative Liabilities At Fair Value
InterestRateDerivativeLiabilitiesAtFairValue
6790000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43771000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52671000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103146000
CY2021Q2 anip Cortrophin Pre Launch Charges
CortrophinPreLaunchCharges
500000
anip Cortrophin Pre Launch Charges
CortrophinPreLaunchCharges
600000
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73855000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48625000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138332000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103146000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18818000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18151000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44715000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18075000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73855000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48625000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138332000

Files In Submission

Name View Source Status
0001023024-22-000017-index-headers.html Edgar Link pending
0001023024-22-000017-index.html Edgar Link pending
0001023024-22-000017.txt Edgar Link pending
0001023024-22-000017-xbrl.zip Edgar Link pending
anip-20220630.xsd Edgar Link pending
anip-20220630x10q.htm Edgar Link pending
anip-20220630xex10d1.htm Edgar Link pending
anip-20220630xex10d1001.jpg Edgar Link pending
anip-20220630xex10d1002.jpg Edgar Link pending
anip-20220630xex10d1004.jpg Edgar Link pending
anip-20220630xex10d1005.jpg Edgar Link pending
anip-20220630xex10d1009.jpg Edgar Link pending
anip-20220630xex10d1011.jpg Edgar Link pending
anip-20220630xex31d1.htm Edgar Link pending
anip-20220630xex31d2.htm Edgar Link pending
anip-20220630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
anip-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
anip-20220630_lab.xml Edgar Link unprocessable
anip-20220630_def.xml Edgar Link unprocessable
anip-20220630_pre.xml Edgar Link unprocessable
anip-20220630x10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending